D. Boral Capital reaffirmed their buy rating on shares of Coya Therapeutics (NASDAQ:COYA - Free Report) in a report issued on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $18.00 target price on the stock.
Separately, Chardan Capital reaffirmed a "buy" rating and issued a $14.00 price target on shares of Coya Therapeutics in a report on Thursday, March 20th.
Get Our Latest Stock Report on COYA
Coya Therapeutics Stock Down 5.4 %
COYA traded down $0.35 during trading on Tuesday, reaching $6.18. 43,278 shares of the company were exchanged, compared to its average volume of 72,865. Coya Therapeutics has a 12-month low of $4.65 and a 12-month high of $10.24. The company's 50-day moving average is $6.17 and its two-hundred day moving average is $6.40. The company has a market cap of $103.36 million, a price-to-earnings ratio of -9.51 and a beta of 0.49.
Coya Therapeutics (NASDAQ:COYA - Get Free Report) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.14. The firm had revenue of $0.20 million during the quarter, compared to analysts' expectations of $0.10 million. Equities analysts forecast that Coya Therapeutics will post -1.15 earnings per share for the current year.
Institutional Investors Weigh In On Coya Therapeutics
Several hedge funds have recently bought and sold shares of COYA. AIGH Capital Management LLC raised its position in shares of Coya Therapeutics by 85.0% during the 4th quarter. AIGH Capital Management LLC now owns 1,201,152 shares of the company's stock valued at $6,883,000 after buying an additional 551,725 shares in the last quarter. DME Capital Management LP raised its position in Coya Therapeutics by 29.2% during the fourth quarter. DME Capital Management LP now owns 1,646,440 shares of the company's stock valued at $9,434,000 after purchasing an additional 372,414 shares in the last quarter. Newbridge Financial Services Group Inc. bought a new stake in Coya Therapeutics during the fourth quarter worth about $401,000. CM Management LLC boosted its holdings in shares of Coya Therapeutics by 11.1% in the 4th quarter. CM Management LLC now owns 160,000 shares of the company's stock worth $917,000 after purchasing an additional 15,941 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Coya Therapeutics during the 4th quarter valued at about $74,000. 39.75% of the stock is currently owned by institutional investors.
About Coya Therapeutics
(
Get Free Report)
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
See Also
Before you consider Coya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coya Therapeutics wasn't on the list.
While Coya Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
